



Somatic neurofibromatosis type 1 (NF1) inactivation characterizes NF1-associated pilocytic astrocytoma

David H. Gutmann, Michael D. McLellan, Ibrahim Hussain, et al.

Genome Res. 2013 23: 431-439 originally published online December 5, 2012

Access the most recent version at doi:[10.1101/gr.142604.112](https://doi.org/10.1101/gr.142604.112)

References This article cites 66 articles, 12 of which can be accessed free at:
<http://genome.cshlp.org/content/23/3/431.full.html#ref-list-1>

Creative Commons License This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issue publication date (see <http://genome.cshlp.org/site/misc/terms.xhtml>). After six months, it is available under a Creative Commons License (Attribution-NonCommercial 3.0 Unported License), as described at <http://creativecommons.org/licenses/by-nc/3.0/>.

Email Alerting Service Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or [click here](#).



To subscribe to *Genome Research* go to:
<https://genome.cshlp.org/subscriptions>

Research

Somatic neurofibromatosis type 1 (NF1) inactivation characterizes NF1-associated pilocytic astrocytoma

David H. Gutmann,^{1,2,7} Michael D. McLellan,^{3,4} Ibrahim Hussain,¹ John W. Wallis,^{3,4} Lucinda L. Fulton,^{3,4} Robert S. Fulton,^{3,4} Vincent Magrini,^{3,4} Ryan Demeter,^{3,4} Todd Wylie,^{3,4} Cyriac Kandoth,^{3,4} Jeffrey R. Leonard,⁵ Abhijit Guha,⁶ Christopher A. Miller,^{3,4} Li Ding,^{3,4} and Elaine R. Mardis^{2,3,4,7}

¹Department of Neurology, Washington University School of Medicine, St. Louis, Missouri 63110, USA; ²Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri 63110, USA; ³The Genome Institute at Washington University School of Medicine, St. Louis, Missouri 63110, USA; ⁴Department of Genetics, Washington University School of Medicine, St. Louis, Missouri 63110, USA; ⁵Division of Neurosurgery, Washington University School of Medicine, St. Louis, Missouri 63110, USA; ⁶Department of Neurosurgery, University of Toronto, Labatt Brain Tumor Centre, Toronto, Canada M5G 1X8

Low-grade brain tumors (pilocytic astrocytomas) arising in the neurofibromatosis type 1 (NF1) inherited cancer predisposition syndrome are hypothesized to result from a combination of germline and acquired somatic *NF1* tumor suppressor gene mutations. However, genetically engineered mice (GEM) in which mono-allelic germline *Nf1* gene loss is coupled with bi-allelic somatic (glial progenitor cell) *Nf1* gene inactivation develop brain tumors that do not fully recapitulate the neuropathological features of the human condition. These observations raise the intriguing possibility that, while loss of neurofibromin function is necessary for NF1-associated low-grade astrocytoma development, additional genetic changes may be required for full penetrance of the human brain tumor phenotype. To identify these potential cooperating genetic mutations, we performed whole-genome sequencing (WGS) analysis of three NF1-associated pilocytic astrocytoma (PA) tumors. We found that the mechanism of somatic *NF1* loss was different in each tumor (frameshift mutation, loss of heterozygosity, and methylation). In addition, tumor purity analysis revealed that these tumors had a high proportion of stromal cells, such that only 50%–60% of cells in the tumor mass exhibited somatic *NF1* loss. Importantly, we identified no additional recurrent pathogenic somatic mutations, supporting a model in which neuroglial progenitor cell *NF1* loss is likely sufficient for PA formation in cooperation with a proper stromal environment.

[Supplemental material is available for this article.]

NF1 is one of the most common autosomal dominant tumor predisposition syndromes in which affected individuals develop brain tumors. In this regard, 15%–20% of children with NF1 develop World Health Organization (WHO) grade I pilocytic astrocytomas (PAs) (Listernick et al. 1994). These low-grade glial neoplasms typically arise in children <7 yr of age and most commonly occur in the optic pathway (optic nerves, chiasm, and tracts) or in the brainstem (Listernick et al. 1997). Similar to other tumor predisposition syndromes, children with NF1 are born with one mutated, nonfunctional copy of the *NF1* gene, such that loss of the remaining allele in appropriate progenitor cells enables tumorigenesis. Consistent with this “two hit” hypothesis, previous studies of NF1-associated PA (NF1-PA) have demonstrated loss of heterozygosity at the DNA level (Kluwe et al. 2001; Gutmann et al. 2003) and loss of *NF1* protein (neurofibromin) expression (Gutmann et al. 2000).

While *NF1* loss in neuroglial progenitors is necessary for PA formation in individuals with NF1, genetically engineered mice (GEM) with conditional loss of *Nf1* gene expression in neuroglial progenitor cells fail to develop brain tumors (Bajenaru et al. 2002; Zhu et al. 2005). This failure to develop gliomas reflects the need

for cooperating *Nf1*^{+/-} non-neoplastic cells in the tumor microenvironment. In this regard, similar to children with NF1 harboring one nonfunctional and one functional *NF1* allele in every cell of their bodies, *Nf1*^{+/-} mice (one functional and one inactivated *Nf1* allele) with absent neuroglial progenitor *Nf1* expression develop optic gliomas with nearly 100% penetrance (Bajenaru et al. 2003). Similar to their human counterparts, these murine brain tumors exhibit low levels of proliferation, increased numbers of endothelial cells and microglia, and nuclear pleomorphism (Bajenaru et al. 2005; Kim et al. 2010).

Interestingly, these mouse optic gliomas do not fully recapitulate the classic histopathological features of the human tumors, in that they lack Rosenthal fibers and eosinophilic granular bodies (Louis et al. 2007), raising the intriguing possibility that other genetic alterations exist in human NF1-PA. The purpose of the current study was to employ advanced whole-genome sequencing technologies to establish the genomic landscape of human NF1-PA to facilitate the development of improved approaches to the diagnosis and management of these brain tumors.

Results

Whole-genome sequencing (WGS) was performed on three PA-matched normal blood (PBMC) cases from individuals with NF1 established using NIH Consensus Development Conference diagnostic criteria (Stumpff et al. 1988; Gutmann et al. 1997). These

⁷Corresponding authors
E-mail gutmann@neuro.wustl.edu
E-mail emardis@wustl.edu

Article published online before print. Article, supplemental material, and publication date are at <http://www.genome.org/cgi/doi/10.1101/gr.142604.112>.

tumors are difficult to obtain, as they are rarely surgically resected and, when removed, typically provide very limited amounts of frozen tissue for comprehensive analysis. Based on our previous studies (Leonard et al. 2006), we specifically selected three PA tumors that were atypical by virtue of patient age (>7 yr of age at the time of glioma discovery) and tumor location (outside of the optic pathway) to maximize our ability to detect additional causative mutations (Table 1). All of these tumors contained >90% tumor (and not normal surrounding brain) by routine hematoxylin and eosin histopathologic review, exhibited the classic histopathologic features of PA (eosinophilic granule bodies, Rosenthal fibers), had low proliferative indices, and lacked necrotic areas or mitotic figures. Informed consent was obtained for all patients on an active protocol approved by the Washington University School of Medicine Institutional Review Board. We obtained paired end sequencing data to a minimum average depth of >32-fold haploid depth per genome. An overall concordance of >99% was obtained when comparing WGS-derived SNP genotypes with SNP array data at identical genome positions (Supplemental Table 1).

In all three patients, the germline *NF1* mutations were identified based on their presence in both tumor and blood DNA (Table 1; Fig. 1): T01 had a point mutation (c.2002-14) in intron 17 (NM_001042492.2) previously demonstrated to create a novel splice variant (Spurlock et al. 2010); T02 had a germline splice site mutation (c.205-2), while T03 had a germline nonsense mutation (p.W1662*). Despite the use of both PCR and capillary sequencing as well as targeted capture-based sequencing from validation, we only identified a somatic *NF1* gene mutation in T02 (frameshift mutation; p.C2426fs), suggesting that additional second hit mechanisms were responsible for low-grade astrocytoma formation in the other two tumors. Moreover, no mutations were identified in the putative promoter region encompassing 50 kb 5' of the initiation codon.

To exclude the possibility that T01 and T03 retained *NF1* gene expression, we performed immunohistochemistry to demonstrate loss of neurofibromin protein expression in all three NF1-PA tumors (Fig. 2A), a result consistent with complete *NF1* inactivation in NF1-PA tumors. We next sought to define the mechanism(s) underlying loss of the second allele in T01 and T03. Loss of heterozygosity (LOH) analyses were performed using VarScan-2 (Koboldt et al. 2012), requiring a variant allele frequency at heterozygous germline SNPs of $\geq 10\%$ in the normal sample and of either $\leq 5\%$ or $\geq 95\%$ in the tumor (only high-confidence calls were considered) to identify LOH regions. Using this method, we identified a 57.3 Mbp copy-neutral LOH on the q arm of chromosome 17 from position 23.9 Mbp to the telomere, encompassing the *NF1* gene, in T03 (Fig. 2B). Further examination of supporting variant and reference allele frequencies indicated bi-allelic inactivation of the *NF1* gene in this tumor occurred through

duplication of the p.W1662* nonsense germline mutation and loss of the wild-type *NF1* allele.

Since T01 had neither an identified somatic *NF1* mutation nor clear evidence of LOH based on the VarScan analysis of 81 heterozygous sites within the *NF1* gene (mean VAFs: 49.2% in the normal DNA and 55.6% in the tumor DNA), we examined methylation patterns. Using the Illumina Infinium HumanMethylation450 BeadChip, we assayed the three whole-genome-sequenced NF1-PA samples and two additional sporadic PA tumors. Genome-wide analysis comparing T01 with T02 and T03 identified 118 probes clustered in 105 regions that exhibited significantly different methylation (Supplemental Table 2). Upon further examination, no methylation alterations affected genes previously reported to be mutated in sporadic PA tumors (Wimmer et al. 2002b; Tada et al. 2003; Sharma et al. 2005; Deshmukh et al. 2008; Jones et al. 2008; Pfister et al. 2008). For most of the 42 probes localized within the *NF1* gene region, we found that methylation patterns were similar in all five PA tumor samples analyzed. However, as a group, the NF1-PA tumors exhibited increased methylation (greater than two standard deviations) at probe cg21850879 (NCBI 36 chr17:26646069) compared with the sporadic counterparts. Interestingly, in T01 (the tumor lacking a second *NF1* somatic mutation) there was increased methylation (greater than two standard deviations) at probe cg13759778 (NCBI 36 chr17:26648522) compared with T02 and T03. Probe cg13759778 is within 200 bp of the transcription start site of *OMG*, one of three antisense nested genes within intron 27b of the *NF1* gene (intron 36 of NM_001042492.2) (Fig. 2C). While this methylation event occurs in intronic sequences within the *NF1* locus and cannot be definitively demonstrated to cause *NF1* gene silencing, the absence of neurofibromin expression in this tumor is consistent with loss of *NF1* gene expression from this allele. Together, these data support the existence of multiple distinct mechanisms (mutation, LOH, and methylation) underlying somatic *NF1* inactivation in NF1-PA tumors.

Using WGS, we were also able to accurately quantify the *NF1* mutant allele frequencies and determine the relative clonality and cellular heterogeneity of these low-grade glial cell neoplasms (Ding et al. 2012). For clonality estimates, we evaluated data for somatic SNVs in nonrepetitive regions consisting of validated nonsynonymous coding variants, and high-confidence, manually reviewed events in potential regulatory regions, as well as the remaining nonrepetitive portion of the genome, representing a total of 133, 181, and 94 variants for tumors T01, T02, and T03, respectively (Supplemental Tables 3–5). Single clusters identified by kernel density estimation (Fig. 3A) indicated that each tumor consisted primarily of a single founding clone having no subclones.

We used these analyses to calculate tumor purity, and found that these tumors were composed of 49%–64% non-neoplastic

Table 1. Clinical attributes and *NF1* mutations in the three NF1-PA tumors

ID	Age	Sex	Tumor location	Mutation class	Type	NCBI 36 position	Alleles	Effect ^a	Status	Validation VAF ^b tumor	Validation VAF ^b normal
T01	20	Male	Lower medulla	de novo splice site	SNP	Chr17:26577565	C > G	p.D668fs	Germline	64.7%	47.6%
T02	18	Female	Hypothalamus	Splice site	SNP	Chr17:26510152	A > C	p.R69fs	Germline	49.7%	44.8%
T02	18	Female	Hypothalamus	Frameshift	DEL	Chr17:26700349	T > —	p.C2426fs	Somatic	23.4%	0%
T03	12	Female	Temporal lobe	Nonsense	SNP	Chr17:26677113	G > A	p.W1662*	Germline + LOH	75.3%	46.7%

^aTranscript NM_001042492.

^bVariant allele frequency.




Figure 1. *NF1* truncation mutations in three whole-genome-sequenced *NF1*-PA tumors. The locations of all truncation mutations are designated with a circle mapped to transcript NM_001042492. Truncating mutations were initially identified in WGS data and further validated with targeted approaches. Predicted functional effects are based on transcript NM_001042492. In patient T03, a somatic, copy-neutral LOH of 57.3 Mbp resulted in duplication of the p.W1662* germline variant.

cells. Based on the combination of tumor purity and the coverage obtained from WGS data, the estimated sensitivity of our somatic mutation detection process is 70%. The large contribution of *NF1*^{+/-} non-neoplastic cells to the tumor cellularity is consistent with parallel microglia (CD68⁺ cells) immunostaining results (Fig. 3B), where 35%–55% of the cells in these PA tumors were microglia/macrophages. This level of stromal contamination with microglia/macrophages is similar to that observed in both sporadic low-grade and high-grade gliomas (Simmons et al. 2011).

Next, we evaluated that possibility of large-scale somatic rearrangements in other genes potentially cooperate with *NF1* loss during PA formation or growth by performing copy number alteration analysis of WGS read data using the cnvHMM algorithm (Chen et al. 2012). Importantly, read-count analysis showed no evidence of copy number aberrations (CNA) in the *NF1* gene regions in any tumor (Supplemental Fig. 1). We then employed BreakDancer (Chen et al. 2009) and SquareDancer (derived from CREST [Wang et al. 2011]) to predict structural variants (SVs). Based on the detection of aberrant mate-pair read mapping distance or orientation, BreakDancer predicted 921, 825, and 449 putative somatic SVs in samples T01, T02, and T03, respectively. None of the predicted somatic SVs were supported by reads containing a physical breakpoint identified by SquareDancer, no large deletions were accompanied by corresponding drops in coverage, and no SV events were validated by custom capture or PCR-based validation sequencing. In this analysis, no CNV or SV were confirmed in the *NF1*-PA tumors, thus excluding CNA and SV from possibly altering the *NF1* locus or its partners.

Predicted nonsynonymous somatic mutations that affect coding regions were validated using PCR followed by capillary sequencing (Supplemental Table 3). In contrast to previous reports on PA, we found no copy number changes or mutations in the *BRAF*, *RAS* (including *KRAS*, *NRAS*, and *HRAS*), *MATN2*, *HIPK2*, *P TEN*, *TP53*, *CDKN2A*, or *EGFR* genes (Tada et al. 2003; Fishbein et al. 2005; Sharma et al. 2005; Deshmukh et al. 2008; Jones et al. 2008; Pfister et al. 2008). However, nonsynonymous somatic mutations were identified in *DST* and *SVIL* in patient T01, *OR13C3* in T02, and *GPATCH2*, *FYTTD1*, *ACTBL2*, *PIK3R2*, and *ZNF257* in T03. To address the possibility that these somatically mutated genes could be involved in *NF1*-PA tumorigenesis, we used custom hybrid capture product sequencing to screen the coding exons of *ACTBL2*, *DST*, *GPATCH2*, *OR13C3*, *PIK3R2*, *SVIL*, *FYTTD1*, and *ZNF257* in PA tumor samples from three additional *NF1* patients. No additional somatic mutations were identified in these additional

samples. Due to the low background mutation rate (BMR) in *NF1*-PA tumors compared with other solid tumor types, mutations identified in noncoding regions were not included in the recurrent screening efforts. Previous attempts to identify recurrent noncoding mutations in larger cohorts of solid tumors with higher BMRs have only identified a small number of recurrent mutations outside of coding regions (Ellis et al. 2012).

While these somatic mutations are novel, it is unlikely that they are pathogenic. First, the majority of the mutations identified (*OR13C3*, *ACTBL2*, *FYTTD1*, *PIK3R2*, and *ZNF257*) were revealed to be neutral (conservative changes in the protein sequence by in silico evaluation with Polyphen2 [Adzhubei et al. 2010], SIFT [Ng and Henikoff 2003], and Condel [Gonzalez-Perez and Lopez-Bigas 2011]) using pre-computed values from the Ensembl Variant Effects Predictor (Supplemental Table 3). Second, of the mutations in *DST*, *SVIL*, and *GPATCH2* predicted to be deleterious, none occurred in an annotated functional protein domain related to carcinogenesis (Sigrist et al. 2010). Third, none of these eight mutations were identified in more than a single tumor, and thus were not recurrent in the limited number of these uncommonly banked tumors. Fourth, none of these genes exhibited bi-allelic inactivation either by mutation or methylation.

Finally, it had been previously postulated that the mutation frequency was high in individuals with *NF1*, with estimates ranging between 1.4×10^{-4} (Crowe et al. 1956) and 6.5×10^{-5} gamete/generation (Samuelsson and Axelsson 1981; Huson et al. 1989; Clementi et al. 1990). Here, in contrast, using WGS data, we find that the mutation frequency in *NF1*-PA is relatively low, similar to that of other pediatric solid tumors where carcinogenesis often results from antecedent germline mutations. In T01, T02, and T03, the BMR, excluding noncoding repetitive sequence, was 9.0×10^{-8} , 1.2×10^{-7} , and 6.0×10^{-8} mutations per sequenced base, respectively, comparable with the BMRs of several pediatric retinoblastoma genomes (Zhang et al. 2012a) (2.0×10^{-8} , 5.0×10^{-8} , 8.0×10^{-8} , and 9.0×10^{-8}). These mutation frequencies differ slightly from hematological malignancies, such as pediatric TALL and the M1 and M3 subtypes of adult AML (2.0×10^{-8} to 4.1×10^{-8} mutations per base) (Mardis et al. 2009; Welch et al. 2012; Zhang et al. 2012b), and differ markedly from adult solid tumors, such as luminal breast cancer, that often have rates that are orders of magnitude higher (Fig. 3C; Mardis et al. 2009).

Discussion

This study represents the first WGS analysis of low-grade glioma and the first such examination of such tumors arising in the context of a common inherited brain tumor predisposition syndrome. Moreover, these data provide important information about the genomic landscape of *NF1*-PA, the clonal origins of these tumors, the various mechanisms underlying somatic *NF1* tumor suppressor gene inactivation, and the extent of tumor cellular heterogeneity.

First, we employ WGS to show that bi-allelic *NF1* gene inactivation is the primary genomic mutation in two of the three *NF1*-associated PA tumors. While we identified other genetic changes in each of the *NF1*-PA specimens, none of these mutations were found in more than one tumor, none exhibited bi-allelic inactivation, and none were located within a predicted functional domain of the encoded protein. Consistent with our previous studies (Li et al. 2001), no changes in the *TP53*, *CDKN2A*, *RBI*, *EGFR*, or *CDK4* genes were observed. Together, these data favor the time-honored hypothesis that *NF1* loss in the neoplastic cellular compartment is the key mutational driver of *NF1*-PA tumorigenesis.




Figure 2. Mechanism of somatic *NF1* inactivation. (A) Immunohistochemistry using rabbit polyclonal neurofibromin antibodies demonstrates positive immunoreactivity in the normal human brain (HBr). (Inset) Single neuron with neurofibromin expression. In each of the three NF1-PA specimens, no neurofibromin expression was detected. Scale bars, 100 μm . Magnification, 400 \times . Inset, 600 \times . (B) In T03, a somatic copy-neutral LOH of the q arm of chromosome 17 from position 23.9 Mbp to the telomere results in duplication of the *NF1* W1662* germline variant. Shown are the median variant allele frequencies of high-confidence germline heterozygous SNPs identified in the normal DNA in 100,000-bp bins across chromosome 17. The position of the *NF1* gene is indicated. (C) Methylation changes in T01 relative to T02 and T03 from Illumina Infinium HumanMethylation450 arrays for 42 probes spanning the *NF1* genomic region. T01 exhibits increased methylation (>2 standard deviations) at NCBI 36 chr17:26648522 (probe cg13759778). This location is within 200 bp of the transcription start site of *OMG*, one of three antisense nested genes within intron 36 of *NF1* mRNA NM_001042492.2.




Figure 3. NF1-PA tumor clonality, cellular heterogeneity, and mutation rate. (A) Somatic mutation clusters were defined based on allele-specific supporting read counts in whole-genome data for mutations identified in nonrepetitive genomic with diploid copy number. Kernel density estimation indicates a monoclonal origin for each tumor and reveals a substantial proportion of stromal cells in the tumor biopsy with estimated tumor purities of 35%, 51%, and 39% for T01, T02, and T03, respectively. (B) CD68 immunostaining confirms the marked cellular heterogeneity of NF1-PA tumors, with 35%–55% of the cells in these tumors representing microglia/macrophages. Representative photomicrographs are included for each NF1-PA tumor. Scale bar, 100 µm. Magnification, 400×. *Insets*, 600×. (C) BMRs are based on the total sum of somatic mutations identified in all nonrepetitive genomic regions from WGS of three NF1-PA tumors, and compared with pediatric retinoblastoma ($N=4$) (Zhang et al. 2012a), pediatric TALL ($N=8$) (Zhang et al. 2012b), the M1 and M3 subtypes of adult AML ($N=25$) (Welch et al. 2012), and luminal breast cancer ($N=46$).

Second, we demonstrate that NF1-PA have a monoclonal origin, similar to their sporadic counterparts (Payton et al. 2011). While the majority of studies that examined clonal origins of glioma using single X-chromosome loci, fluorescent in situ hybridization, microsatellite markers, or single substitute mutation methods demonstrated a monoclonal pattern (Kattar et al. 1997; Zhu et al. 1997; Mueller et al. 2001), there are reports of gliomas exhibiting a multiclonal origin (Dong et al. 2002; Gomori et al. 2002; Vital et al. 2010). Since the few brain tumors with presumed polyclonal origins were high-grade gliomas, we favor a model of low-grade pediatric astrocytoma development in which tumors arise from a single population of glial progenitors during fetal or early postnatal life.

Third, we show that there exist multiple possible mechanisms of somatic *NF1* gene silencing, including LOH, mutation, and methylation. While LOH and mutation have been reported in

numerous NF1-associated tumor types, prior studies on another NF1-associated tumor (peripheral nerve sheath tumor; neurofibroma) revealed that *NF1* promoter hypermethylation is a rare “second hit” event (Horan et al. 2000; Wimmer et al. 2002a; Harder et al. 2004; Fishbein et al. 2005). While we have not demonstrated a direct cause-and-effect relationship between *NF1* locus hypermethylation and reduced neurofibromin (immunohistochemistry) expression was observed in T01 is consistent with this conclusion. Our observations coupled with results on another childhood nervous system tumor, retinoblastoma (Zhang et al. 2012a), suggest that somatic tumor suppressor gene inactivation by methylation may represent another mode to achieve bi-allelic inactivation. However, it is possible that other mechanisms are operative, such as epigenetic silencing by microRNA.

Last, *Nf1* GEM optic glioma models have been particularly instructive in elucidating the requirements for tumorigenesis. Collectively, these studies have revealed that the unique pattern of low-grade astrocytoma development (predominantly in the optic pathway/brainstem of children) reflects the coupling of at least two requirements: (1) *Nf1* loss in specific neuroglial progenitor cells (third ventricle or brainstem) during a defined temporal window (embryonic development) (Lee et al. 2010, 2012) and (2) a supportive local microenvironment composed of critical molecular signals (Warrington et al. 2007, 2010) and non-neoplastic cell types (Daginakatte and Gutmann 2007; Daginakatte et al. 2008). The current study emphasizes the significant cellular heterogeneity in human NF1-PA, consistent with previous studies on glioma in which a large proportion of the cellular composition is non-neoplastic cells. One of these stromal cell types is microglia, an immune-like cell, analogous to macrophages outside of the central nervous system (Graeber et al. 2002; Watters et al. 2005). The importance of these stromal cells to NF1 glioma growth is further supported by several studies using *Nf1* GEM strains. In these experiments, pharmacologic or genetic silencing of microglia reduces glioma growth and proliferation (Daginakatte and Gutmann 2007; Daginakatte et al. 2008; Simmons et al. 2011). The mechanism underlying their glioma-promoting properties has not been fully elucidated, but likely involves the generation of growth factors and chemokines (Daginakatte and Gutmann 2007; Warrington et al. 2007; Wesolowska et al. 2008; Zhai et al. 2011). This potentially instructive contribution of microglia has recently prompted us to apply RNA sequencing methods to more comprehensively define the role of microglia in sporadic PA formation and continued growth.

Methods

Patients

Blood and tumor specimens were obtained from three patients diagnosed with NF1 according to established criteria (Stumpf et al. 1988) treated at Washington University School of Medicine or the University of Toronto under active Human Studies Protocols approved by the Institutional Review Board at the Washington University School of Medicine and the University of Toronto. WGS was performed for tumor and normal DNA from three children with pilocytic astrocytomas. Tumor samples were obtained from banked resected tumors characterized by pathologic examination. Matched nontumor samples were obtained from PBMCs by phlebotomy.

Custom capture hybridization and sequencing

Sequencing libraries were hybridized to biotinylated 120-mer oligonucleotide probes designed to cover all coding exons of target genes. Illumina library quantification was completed using the KAPA SYBR FAST qPCR Kit (KAPA Biosystems).

Capture alignment, de-duplication, and BAM file generation

Illumina reads were aligned individually to the Ensembl release 45 version of Human NCBI Build 36 using BWA 2 v0.5.7 with soft trimming (-q 5) as previously reported (Mardis et al. 2009). For each sample, individual lane alignments in BAM format were merged together using SAMtools 3 r544. Duplicates were marked in the merged BAM files by the MarkDuplicates class of Picard 4 v1.17. Reads with mapping quality of zero, or that were marked as duplicates by Picard, were excluded from further analysis.

SNV and small indel detection

Candidate point mutations were predicted using SomaticSniper, previously referred to as glfSomatic 1.5. Putative SNVs with somatic score ≥ 40 and average mapping quality ≥ 40 were considered high-confidence (HC); all others were deemed low-confidence (LC). Small indels were predicted using a combination of GATK 6 IndelGenotyper, Pindel 7, and a modified version of SAMtools 3. Both SNVs and indels were annotated using gene structure, conservation information, and regulatory potential, then binned as previously described (Mardis et al. 2009). High-confidence non-coding mutations in nonrepetitive genomic regions were visualized to filter false positives, while nonsynonymous coding mutations were selected for additional PCR- and custom-capture-based validation sequencing.

Copy number variation (CNV) analysis

Copy number calls from WGS data were generated using the cnvHMM algorithm (<http://genome.wustl.edu/software/cnvhmm>). First, cnvHMM divided the genome into nonoverlapping windows 10 kbp in size. For each window, the raw copy number was estimated as the number of reads confidently mapped (mapping quality >35) divided by the median of such value across all windows in the genome, then multiplied by two (to reflect diploid genomes). A hidden Markov model (HMM) was then used to perform the segmentation. Each state in the HMM corresponds to a discrete copy number value. The emission probability was modeled as a single Gaussian probability density function. A standard Viterbi algorithm was used to estimate the HMM parameters and determined the segmentation. We derived copy number altered regions (CNARs) by comparing the segmentation of the tumor genome versus that of the normal genome. A log likelihood ratio (LLR) score was computed for each CNAR to quantify the possibility of being a true CNAR from being the null (copy number neutral) hypothesis. Calls with LLR score <20 were dropped from further consideration.

Structural variation (SV) analysis

Structural variants (SVs) were predicted by BreakDancer 9 with TIGRA_SV assembly 10, SquareDancer (Wang et al. 2011), and Pindel (Ye et al. 2009). Copy number differences with regions of SV were determined by BreakDancer (Chen et al. 2009). Putative SVs from BreakDancer were chosen for localized, de novo assembly if they (1) had at least two supporting discordant read pairs in the tumor, but none in the normal, (2) were supported by a copy number change of >0.5 in the SV region, (3) affected a coding exon, or (4) had one or more breakpoints in any part of a known cancer gene. SV regions were defined as ± 500 bp from the predicted breakpoints. The depth-weighted average contig length was used as a quality measure of the assembly:

$$q = \frac{\sum_{i=0}^{M-1} d_i l_i}{\sum_{i=0}^{M-1} d_i}$$

where l_i and d_i are the length and the average depth of contig i , respectively, and M is the total number of contigs in the TIGRA assembly. Short contigs (<30 bp) that are assembled from the homopolymer reads are excluded in the calculation. We found this statistic properly summarizes both the size and the coverage and therefore is more informative to measure the assembly quality than the N50 size. Based on our manual examination of the alignment results, we found that the high-quality assemblies that

contain valid sequence frequently have $q > 100$ bp. Once assembled, contigs were aligned to their respective local reference sequences (SV region ± 700 bp; NCBI Build b36) using `cross_match v1.080721` with the parameters “`-bandwidth 20 -mismatch 20 -minscore 25 -penalty -10 -discrep_lists -tags -gap_init -10 -gap_ext -1`”. Contigs whose alignments had more than two segments or were significantly different from the reference (one segment with substitution >0.006 or indel rate of >0.002 ; or two segments with substitution rate >0.005 , indel rate of >0.001 , or more than five inserted/deleted bases) were removed. A complementary in-house algorithm, SquareDancer, was used to identify candidate SVs by utilizing soft-clipping information from the BWA aligner. Large deletions and moderately sized insertions were also predicted using a modified version of the Pindel 7 tool. Pindel calls with read support in the tumor but not the normal, as well as calls supported by copy number evidence from cnvHMM (copy number >0.5) were identified. Candidate SVs from BreakDancer, SquareDancer, and Pindel SV regions from different methods that overlapped $>75\%$ (allowing a buffer of ± 50 bp) were merged into a single event.

PCR-based validation and screening

Using Primer3, universal-tailed PCR primers were designed to amplify all coding exons of *NF1* in addition to the localized region surrounding all predicted nonsynonymous coding variants. Tumor DNA was PCR-amplified using AmpliTaq Gold PCR Master mix and sequenced using BigDye 3.1 Sequencing Kits and loaded on ABI 3730xl capillary sequencers. Data were assembled using Consed and putative mutations identified using Polyscan and Polyphred. All putative variants were visually reviewed to eliminate artifacts.

Hybridization validation data analysis

To validate predicted nonsynonymous coding SNVs and small (<3 bp) indels, we used VarScan 2.2.11 with the following parameters: `-mincoverage 30 -min-var-freq 0.08 -P-value 0.10 -somatic-P-value 0.01 -validation 1`. To validate low-frequency (2%–8%) SNVs, we reran VarScan with adjusted parameters: `-min-coverage 100 -min-var-freq 0.02 -P-value 0.10 -somatic-P-value 0.01 -validation 1`. In validation mode, VarScan reads data from tumor and normal samples simultaneously, performing pairwise comparisons at every position covered in both samples. Each position is classified as Reference (wild type), Germline, LOH, or Somatic, based upon a comparison of the consensus genotypes and supporting read counts (Fisher’s exact test). Positions called Somatic are further subjected to our internally developed false-positive filter that removes sequencing- and alignment-related artifacts using several criteria (read count, mapping quality, average read position, strand representation, homopolymer-like sequence context, mismatch quality sum difference, trimmed read length, Q2 distance).

Mutation rate and spectrum analysis

Mutation rate analyses utilized validated nonsynonymous coding SNVs, high-confidence SNVs in potential regulatory regions, and SNVs in nonrepetitive regions that passed visual inspection. For the mutation rate calculation, the number of SNVs in each bin was compared to the overall size of the exome, noncoding genome with regulatory potential, and remaining nonrepetitive genome, which on NCBI Build 36, consisted of 43.89 Mbp, 248.21 Mbp, and 1198.99 Mbp, respectively. The individual mutation rates (mutations per megabase) were calculated independently then combined for all three bins to determine the overall mutation rate.

Methylation analysis

Methylation state was determined using the Infinium HumanMethylation450 BeadChip Kit (Gu et al. 2010; Bibikova et al. 2011; Sandoval et al. 2011). The HumanMethylation450 chip arrays $>485,000$ methylation sites per sample at single-nucleotide resolution. Aside from covering 96% of CpG islands, sites are also associated with regions of biological interest—e.g., miRNA promoter regions, differentially methylated sites identified in tumor versus normal (multiple forms of cancer) and across several tissue types—for epigenome-wide association studies (EWAS). Of the $>485,000$ sites on the Infinium array, 42 of the probes are located within the *NF1* gene footprint (including upstream promoter region). The *NF1* probes include UCSC-defined CpG island annotation (i.e., island, shore, and shelf designations). The 42 probes culled from the *NF1* gene footprint have 13 probes associated with genes on the opposite strand of *NF1*: six for *OMG*, two for *EVI2B*, and five for *EVI2A*. These 42 probes were reviewed for methylation state across three different pilocytic astrocytomas from patients with known *NF1* defects and two spontaneous pilocytic astrocytomas without *NF1* defects. Infinium chip Beta-values (the ratio of the methylated probe intensity and the overall intensity: the sum of methylated and unmethylated probe intensities) were converted to M-values (log₂ ratio of the intensities of methylated probe versus unmethylated probe) using the MethyLumi package from Bioconductor19 (Davis et al. 2012). Illumina’s raw IDAT files were fed to the MethyLumi package for value conversion. Resulting M-values were tracked/interrogated across our samples by converting to YAML format, with subsequent parsing mediated by Perl scripts developed in-house. In this manner, M-values related to the 42 *NF1*-specific probes were collected and contrasted for our samples. Values were imported and manually reviewed as custom tracks in the UCSC Genome Browser (Kent et al. 2002) as methylation probe tracks, as well as M-value heat map blocks across our tumor and sporadic samples. Differences in M-values (Δ M-values) were calculated across our samples, in a pairwise round-robin fashion, with standard deviation used to assess significance in differential change. As values were assessed localized to the 42 probe *NF1* gene region, a follow-up global assessment was undertaken for all 485,000+ probes across all samples, to review global significance of change, as Δ M-values, between samples. Our five tumor samples were evaluated in an all-versus-all fashion with 4,855,770 comparison values sampled in total. The mean Δ M-value was 0.52, standard deviation being 0.58. Any change in M-value >2.24 would be 3 standard deviations. For our purposes, we scaled back to an absolute Δ M-value of ≥ 2.0 in value being “significant”. This provided 137,628 comparisons matching the criteria (or only 2.83% of the total 4,855,770 cross-comparisons being relatively significant). Accepting these values as being representative of the sensitivity for the technology (i.e., not “error”), any Δ M-value ≥ 2.0 within *NF1* would be considered significant. In addition, we performed a *t*-test to identify regions genome-wide exhibiting significantly differential methylation per probe. We clustered together probes 200 bp or closer with $P \leq 0.05$ and determined 118 such probes in 105 clusters that exhibited significantly differential methylation. These regions were further annotated by identifying all genes occurring within 10 kbp (Supplemental Table 2).

Immunohistochemistry and qRT-PCR

Immunohistochemistry and real-time quantitative RNA RT-PCR were performed as previously reported (Gutmann et al. 2000; Sharma et al. 2007).

Data access

All sequence data have been submitted to the database of Genotypes and Phenotypes (dbGaP) (<http://www.ncbi.nlm.nih.gov/gap>) under accession number phs000563.v1.p1.

Acknowledgments

We thank Mr. Ryan Emmett for expert technical assistance and Sonika Dahiya for neuropathological consultation. We acknowledge the efforts of the following people and groups at The Genome Institute for their contributions to this manuscript: the Analysis Pipeline group for developing the automated analysis pipelines that generated alignments and somatic variants; the LIMS group for developing tools to manage validation array ordering, capture, and sequencing, Joelle Veizer and Heather Schmidt for manual review of predicted mutations; and Joshua F. McMichael and Charles Lu for their assistance preparing the tables and figures. This work was supported by a Doris Duke Fellowship (to I.H.) and core facilities in the Washington University CTSA (UL1-RR024992). We dedicate this work in memory of our dear colleague and friend, Abhijit Guha, who died during the final preparation of this manuscript.

Author contributions: D.H.G., E.R.M., and L.D. designed the experiments, L.L.F. and R.S.F. supervised data production and validation processes, L.D., M.D.M., and J.W.W. led the data analysis, V.M., R.D., C.A.M., C.K., T.W., and M.D.M. performed data analysis, L.D., J.W.W., T.W., and M.D.M. prepared figures and tables, A.G. and J.R.L. provided samples and clinical data, T.W., R.D., and V.M. performed laboratory experiments, D.H.G. and E.R.M. developed the project concept, and I.H., J.W.W., M.D.M., L.D., E.R.M., and D.H.G. wrote the manuscript.

References

- Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS, Sunyaev SR. 2010. A method and server for predicting damaging missense mutations. *Nat Methods* **7**: 248–249.
- Bajenaru ML, Zhu Y, Hedrick NM, Donahoe J, Parada LF, Gutmann DH. 2002. Astrocyte-specific inactivation of the neurofibromatosis 1 gene (*NF1*) is insufficient for astrocytoma formation. *Mol Cell Biol* **22**: 5100–5113.
- Bajenaru ML, Hernandez MR, Perry A, Zhu Y, Parada LF, Garbow JR, Gutmann DH. 2003. Optic nerve glioma in mice requires astrocyte *Nf1* gene inactivation and *Nf1* brain heterozygosity. *Cancer Res* **63**: 8573–8577.
- Bajenaru ML, Garbow JR, Perry A, Hernandez MR, Gutmann DH. 2005. Natural history of neurofibromatosis 1-associated optic nerve glioma in mice. *Ann Neurol* **57**: 119–127.
- Bibikova M, Barnes B, Tsan C, Ho V, Klotzle B, Le JM, Delano D, Zhang L, Schroth GP, Gunderson KL, et al. 2011. High density DNA methylation array with single CpG site resolution. *Genomics* **98**: 288–295.
- Chen K, Wallis JW, McLellan MD, Larson DE, Kalicki JM, Pohl CS, McGrath SD, Wendt MC, Zhang Q, Locke DP, et al. 2009. BreakDancer: An algorithm for high-resolution mapping of genomic structural variation. *Nat Methods* **6**: 677–681.
- Chen K, Wallis JW, Kandath C, Kalicki-Veizer JM, Mungall KL, Mungall AJ, Jones SJ, Marra MA, Ley TJ, Mardis ER, et al. 2012. BreakFusion: Targeted assembly-based identification of gene fusions in whole transcriptome paired-end sequencing data. *Bioinformatics* **28**: 1923–1924.
- Clementi M, Barbujani G, Turolla L, Tenconi R. 1990. Neurofibromatosis-1: A maximum likelihood estimation of mutation rate. *Hum Genet* **84**: 116–118.
- Crowe FW, Schull WJ, Neel JV. 1956. *A clinical pathological and genetic study of multiple neurofibromatosis*. Thomas, Springfield, IL.
- Daginakatte GC, Gutmann DH. 2007. Neurofibromatosis-1 (*NF1*) heterozygous brain microglia elaborate paracrine factors that promote *Nf1*-deficient astrocyte and glioma growth. *Hum Mol Genet* **16**: 1098–1112.
- Daginakatte GC, Gianino SM, Zhao NW, Parsadanian AS, Gutmann DH. 2008. Increased c-Jun-NH₂-kinase signaling in neurofibromatosis-1 heterozygous microglia drives microglia activation and promotes optic glioma proliferation. *Cancer Res* **68**: 10358–10366.
- Davis S, Du P, Bilke S, Triche T Jr, Bootwalla M. 2012. methylumi: Handle Illumina methylation data. Bioconductor R package version 1.9.9. <http://www.bioconductor.org/packages/release/bioc/html/methylumi.html>.
- Deshmukh H, Yeh TH, Yu J, Sharma MK, Perry A, Leonard JR, Watson MA, Gutmann DH, Nagarajan R. 2008. High-resolution, dual-platform aCGH analysis reveals frequent *HIPK2* amplification and increased expression in pilocytic astrocytomas. *Oncogene* **27**: 4745–4751.
- Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, Welch JS, Ritchey JK, Young MA, Lamprecht T, McLellan MD, et al. 2012. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. *Nature* **481**: 506–510.
- Dong ZQ, Pang JC, Tong CY, Zhou LF, Ng HK. 2002. Clonality of oligoastrocytomas. *Hum Pathol* **33**: 528–535.
- Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW, Van Tine BA, Hoog J, Goiffon RJ, Goldstein TC, et al. 2012. Whole-genome analysis informs breast cancer response to aromatase inhibition. *Nature* **486**: 353–360.
- Fishbein L, Eady B, Sanek N, Muir D, Wallace MR. 2005. Analysis of somatic *NF1* promoter methylation in plexiform neurofibromas and Schwann cells. *Cancer Genet Cytogenet* **157**: 181–186.
- Gomori E, Fulop Z, Meszaros I, Doczi T, Matolcsy A. 2002. Microsatellite analysis of primary and recurrent glial tumors suggests different modalities of clonal evolution of tumor cells. *J Neuropathol Exp Neurol* **61**: 396–402.
- Gonzalez-Perez A, Lopez-Bigas N. 2011. Improving the assessment of the outcome of nonsynonymous SNVs with a consensus deleteriousness score, Condel. *Am J Hum Genet* **88**: 440–449.
- Graeber MB, Scheithauer BW, Kreutzberg GW. 2002. Microglia in brain tumors. *Glia* **40**: 252–259.
- Gu H, Bock C, Mikkelsen TS, Jager N, Smith ZD, Tomazou E, Gnirke A, Lander ES, Meissner A. 2010. Genome-scale DNA methylation mapping of clinical samples at single-nucleotide resolution. *Nat Methods* **7**: 133–136.
- Gutmann DH, Aylsworth A, Carey JC, Korf B, Marks J, Peyeritz RE, Rubenstein A, Viskochil D. 1997. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. *JAMA* **278**: 51–57.
- Gutmann DH, Donahoe J, Brown T, James CD, Perry A. 2000. Loss of neurofibromatosis 1 (*NF1*) gene expression in *NF1*-associated pilocytic astrocytomas. *Neuropathol Appl Neurobiol* **26**: 361–367.
- Gutmann DH, James CD, Poyhonen M, Louis DN, Ferner R, Guha A, Hariharan S, Viskochil D, Perry A. 2003. Molecular analysis of astrocytomas presenting after age 10 in individuals with *NF1*. *Neurology* **61**: 1397–1400.
- Harder A, Rosche M, Reuss DE, Holtkamp N, Uhlmann K, Friedrich R, Mautner VF, von Deimling A. 2004. Methylation analysis of the neurofibromatosis type 1 (*NF1*) promoter in peripheral nerve sheath tumours. *Eur J Cancer* **40**: 2820–2828.
- Horan MP, Cooper DN, Upadhyaya M. 2000. Hypermethylation of the neurofibromatosis type 1 (*NF1*) gene promoter is not a common event in the inactivation of the *NF1* gene in *NF1*-specific tumours. *Hum Genet* **107**: 33–39.
- Huson SM, Compston DA, Harper PS. 1989. A genetic study of von Recklinghausen neurofibromatosis in south east Wales. II. Guidelines for genetic counselling. *J Med Genet* **26**: 712–721.
- Jones DT, Kocalkowski S, Liu L, Pearson DM, Backlund LM, Ichimura K, Collins VP. 2008. Tandem duplication producing a novel oncogenic *BRAF* fusion gene defines the majority of pilocytic astrocytomas. *Cancer Res* **68**: 8673–8677.
- Kattar MM, Kupsky WJ, Shimoyama RK, Vo TD, Olson MW, Bargar GR, Sarkar FH. 1997. Clonal analysis of gliomas. *Hum Pathol* **28**: 1166–1179.
- Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, Zahler AM, Haussler D. 2002. The human genome browser at UCSC. *Genome Res* **12**: 996–1006.
- Kim KY, Ju WK, Hegedus B, Gutmann DH, Ellisman MH. 2010. Ultrastructural characterization of the optic pathway in a mouse model of neurofibromatosis-1 optic glioma. *Neuroscience* **170**: 178–188.
- Kluwe L, Hagel C, Tatagiba M, Thomas S, Stavrou D, Ostertag H, von Deimling A, Mautner VF. 2001. Loss of *NF1* alleles distinguish sporadic from *NF1*-associated pilocytic astrocytomas. *J Neuropathol Exp Neurol* **60**: 917–920.
- Koboldt DC, Zhang Q, Larson DE, Shen D, McLellan MD, Lin L, Miller CA, Mardis ER, Ding L, Wilson RK. 2012. VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencing. *Genome Res* **22**: 568–576.
- Lee DY, Yeh TH, Emmett RJ, White CR, Gutmann DH. 2010. Neurofibromatosis-1 regulates neuroglial progenitor proliferation and glial differentiation in a brain region-specific manner. *Genes Dev* **24**: 2317–2329.

- Lee DY, Gianino SM, Gutmann DH. 2012. Innate neural stem cell heterogeneity determines the patterning of glioma formation in children. *Cancer Cell* **22**: 131–138.
- Leonard JR, Perry A, Rubin JB, King AA, Chicoine MR, Gutmann DH. 2006. The role of surgical biopsy in the diagnosis of glioma in individuals with neurofibromatosis-1. *Neurology* **67**: 1509–1512.
- Li J, Perry A, James CD, Gutmann DH. 2001. Cancer-related gene expression profiles in NF1-associated pilocytic astrocytomas. *Neurology* **56**: 885–890.
- Listernick R, Charrow J, Greenwald M, Mets M. 1994. Natural history of optic pathway tumors in children with neurofibromatosis type 1: A longitudinal study. *J Pediatr* **125**: 63–66.
- Listernick R, Louis DN, Packer RJ, Gutmann DH. 1997. Optic pathway gliomas in children with neurofibromatosis 1: Consensus statement from the NF1 Optic Pathway Glioma Task Force. *Ann Neurol* **41**: 143–149.
- Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. 2007. *The WHO classification of tumours of the central nervous system*. IARC, Lyon.
- Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K, Koboldt DC, Fulton RS, Delehaunty KD, McGrath SD, et al. 2009. Recurring mutations found by sequencing an acute myeloid leukemia genome. *N Engl J Med* **361**: 1058–1066.
- Mueller W, Lass U, Herms J, Kuchelmeister K, Bergmann M, von Deimling A. 2001. Clonal analysis in glioblastoma with epithelial differentiation. *Brain Pathol* **11**: 39–43.
- Ng PC, Henikoff S. 2003. SIFT: Predicting amino acid changes that affect protein function. *Nucleic Acids Res* **31**: 3812–3814.
- Payton JE, Schmidt J, Yu J, Lusic EA, Watson MA, Gutmann DH. 2011. Genome-wide polymorphism analysis demonstrates a monoclonal origin of pilocytic astrocytoma. *Neuropathol Appl Neurobiol* **37**: 321–325.
- Pfister S, Janzarik WG, Remke M, Ernst A, Werft W, Becker N, Toedt G, Wittmann A, Kratz C, Olbrich H, et al. 2008. BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. *J Clin Invest* **118**: 1739–1749.
- Samuelsson B, Axelsson R. 1981. Neurofibromatosis. A clinical and genetic study of 96 cases in Gothenburg, Sweden. *Acta Derm Venereol Suppl (Stockh)* **95**: 67–71.
- Sandoval J, Heyn H, Moran S, Serra-Musach J, Pujana MA, Bibikova M, Esteller M. 2011. Validation of a DNA methylation microarray for 450,000 CpG sites in the human genome. *Epigenetics* **6**: 692–702.
- Sharma MK, Zehnbauser BA, Watson MA, Gutmann DH. 2005. RAS pathway activation and an oncogenic RAS mutation in sporadic pilocytic astrocytoma. *Neurology* **65**: 1335–1336.
- Sharma MK, Mansur DB, Reifenberger G, Perry A, Leonard JR, Aldape KD, Albin MG, Emmett RJ, Loeser S, Watson MA, et al. 2007. Distinct genetic signatures among pilocytic astrocytomas relate to their brain region origin. *Cancer Res* **67**: 890–900.
- Sigrist CJ, Cerutti L, de Castro E, Langendijk-Genevaux PS, Bulliard V, Bairoch A, Hulo N. 2010. PROSITE, a protein domain database for functional characterization and annotation. *Nucleic Acids Res* **38**: D161–D166.
- Simmons GW, Pong WW, Emmett RJ, White CR, Gianino SM, Rodriguez FJ, Gutmann DH. 2011. Neurofibromatosis-1 heterozygosity increases microglia in a spatially and temporally restricted pattern relevant to mouse optic glioma formation and growth. *J Neuropathol Exp Neurol* **70**: 51–62.
- Spurlock G, Knight SJ, Thomas N, Kiehl TR, Guha A, Upadhyaya M. 2010. Molecular evolution of a neurofibroma to malignant peripheral nerve sheath tumor (MPNST) in an NF1 patient: Correlation between histopathological, clinical and molecular findings. *J Cancer Res Clin Oncol* **136**: 1869–1880.
- Stumpf DA, Alksne JF, Annegers JF. 1988. Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. *Arch Neurol* **45**: 575–578.
- Tada K, Kochi M, Saya H, Kuratsu J, Shiraishi S, Kamiryo T, Shinjima N, Ushio Y. 2003. Preliminary observations on genetic alterations in pilocytic astrocytomas associated with neurofibromatosis 1. *Neuro Oncol* **5**: 228–234.
- Vital AL, Taberero MD, Crespo I, Rebelo O, Tao H, Gomes F, Lopes MC, Orfao A. 2010. Intratumoral patterns of clonal evolution in gliomas. *Neurogenetics* **11**: 227–239.
- Wang J, Mullighan CG, Easton J, Roberts S, Heatley SL, Ma J, Rusch MC, Chen K, Harris CC, Ding L, et al. 2011. CREST maps somatic structural variation in cancer genomes with base-pair resolution. *Nat Methods* **8**: 652–654.
- Warrington NM, Woerner BM, Daginakatte GC, Dasgupta B, Perry A, Gutmann DH, Rubin JB. 2007. Spatiotemporal differences in CXCL12 expression and cyclic AMP underlie the unique pattern of optic glioma growth in neurofibromatosis type 1. *Cancer Res* **67**: 8588–8595.
- Warrington NM, Gianino SM, Jackson E, Goldhoff P, Garbow JR, Piwnicka-Worms D, Gutmann DH, Rubin JB. 2010. Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1. *Cancer Res* **70**: 5717–5727.
- Watters JJ, Schartner JM, Badie B. 2005. Microglia function in brain tumors. *J Neurosci Res* **81**: 447–455.
- Welch JS, Ley TJ, Link DC, Miller CA, Larson DE, Koboldt DC, Wartman LD, Lamprecht TL, Liu F, Xia J, et al. 2012. The origin and evolution of mutations in acute myeloid leukemia. *Cell* **150**: 264–278.
- Wesolowska A, Kwiatkowska A, Slomnicki L, Dembinski M, Master A, Sliwa M, Franciszkievicz K, Chouaib S, Kaminska B. 2008. Microglia-derived TGF- β as an important regulator of glioblastoma invasion—an inhibition of TGF- β -dependent effects by shRNA against human TGF- β type II receptor. *Oncogene* **27**: 918–930.
- Wimmer K, Eckart M, Meyer-Puttlitz B, Fonatsch C, Pietsch T. 2002a. Mutational and expression analysis of the *NF1* gene argues against a role as tumor suppressor in sporadic pilocytic astrocytomas. *J Neuropathol Exp Neurol* **61**: 896–902.
- Wimmer K, Zhu XX, Rouillard JM, Ambros PF, Lamb BJ, Kuick R, Eckart M, Weinhausl A, Fonatsch C, Hanash SM. 2002b. Combined restriction landmark genomic scanning and virtual genome scans identify a novel human homeobox gene, *ALX3*, that is hypermethylated in neuroblastoma. *Genes Chromosomes Cancer* **33**: 285–294.
- Ye K, Schulz MH, Long Q, Apweiler R, Ning Z. 2009. Pindel: A pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads. *Bioinformatics* **25**: 2865–2871.
- Zhai H, Heppner FL, Tsirka SE. 2011. Microglia/macrophages promote glioma progression. *Glia* **59**: 472–485.
- Zhang J, Benavente CA, McEvoy J, Flores-Otero J, Ding L, Chen X, Ulyanov A, Wu G, Wilson M, Wang J, et al. 2012a. A novel retinoblastoma therapy from genomic and epigenetic analyses. *Nature* **481**: 329–334.
- Zhang J, Ding L, Holmfeldt L, Wu G, Heatley SL, Payne-Turner D, Easton J, Chen X, Wang J, Rusch M, et al. 2012b. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. *Nature* **481**: 157–163.
- Zhu JJ, Leon SP, Folkert RD, Guo SZ, Wu JK, Black PM. 1997. Evidence for clonal origin of neoplastic neuronal and glial cells in gangliogliomas. *Am J Pathol* **151**: 565–571.
- Zhu Y, Harada T, Liu L, Lush ME, Guignard F, Harada C, Burns DK, Bajenaru ML, Gutmann DH, Parada LF. 2005. Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation. *Development* **132**: 5577–5588.

Received May 7, 2012; accepted in revised form November 26, 2012.